diketopiperazines

Preferred Label : diketopiperazines;

MeSH definition : Piperazines with two keto oxygens.;

MeSH synonym : piperazinediones; diketopiperazine compounds; diketopiperazine;

MeSH hyponym : diketopiperazine ion (1-); pyrrolopiperazinediones; Pyrrolodiketopiperazines;

MeSH Related Number : diketopiperazine ion (1-); 35054-35-4;

Related CAS MeSH : 35054-35-4 (Diketopiperazine ion (1-));

Wikipedia link : https://en.wikipedia.org/wiki/Diketopiperazines;

Is substance : O;

Details

Origin ID

D054659;

UMLS CUI

C0058171;

Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Pharmacological action(s)
- anti-bacterial agents [MeSH Descriptor]
Record concept(s)
- diketopiperazine ion (1-) [MeSH concept]
- diketopiperazines [MeSH concept]
- pyrrolopiperazinediones [MeSH concept]
Related MeSH Supplementary Concept(s)
- (R)-2-(2-(furan-2-yl)-oxoethyl)octahydropyrrolo(1,2-a)pyrazine-1,4-dione [MeSH Supplementary Concept]
- 1,4-N,N-(phenylethyl)piperazine-2,5-dione [MeSH Supplementary Concept]
- 2,5-dioxopiperazine [MeSH Supplementary Concept]
- 3-((5-tert-butyl-1H-imidazol-4-yl)methylene)-6-(2,5-difluorobenzylidene)piperazine-2,5-dione [MeSH Supplementary Concept]
- 3-((6-((5-benzylidene-3,6-dioxopiperazin-2-ylidene)methyl)pyridin-3-yloxy)methyl)benzoic acid [MeSH Supplementary Concept]
- 3-(3-benzoylbenzylidene)-6-((5-tert-butyl-1H-imidazol-4-yl)methylene)piperazine-2,5-dione [MeSH Supplementary Concept]
- 3-(6-isobutyl-9-methoxy-1,4-dioxo-1,2,3,4,6,7,12,12a-octahydropyrazino(1',2'-1,6)pyrido(3,4-b)indol-3-yl)propionic acid tert-butyl ester [MeSH Supplementary Concept]
- 3-(aminomethyl)piperazine-2,5-dione [MeSH Supplementary Concept]
- 4,4'-(1,2-dimethyl-1,2-ethanediyl)bis-2,6-piperazinedione [MeSH Supplementary Concept]
- 4-(3,3,5,5-tetra-methyl-2,6-dioxo-4-oxylpiperazin-1-yl)phenylglycine [MeSH Supplementary Concept]
- 4-(4-((1-butyl-3-(cyclohexyl(hydroxy)methyl)-2,5-dioxo-1,4,9-triazaspiro(5.5)undec-9-yl)methyl)phenoxy)benzoic acid [MeSH Supplementary Concept]
- 5-(aminomethyl)piperazine-2,3-dione [MeSH Supplementary Concept]
- 6,6'-bis(chloromethyl)-1,1',4,4'-tetramethyl-3,3'-(p-phenylenedimethylene)bis(piperazine-2,5-dione) [MeSH Supplementary Concept]
- 7,9-dihydroxy-3-(1H-indol-3-ylmethyl)-8-methoxy-2,3,11,11a-tetrahydro-6H-pyrazino(1,2-b)isoquinoline-1,4-dione [MeSH Supplementary Concept]
- 7-O-methylvariecolortide A [MeSH Supplementary Concept]
- DKP101516 [MeSH Supplementary Concept]
- G226 compound [MeSH Supplementary Concept]
- GSK2395448 [MeSH Supplementary Concept]
- HDN-1 compound [MeSH Supplementary Concept]
- ISA-2011B [MeSH Supplementary Concept]
- K560 compound [MeSH Supplementary Concept]
- KPU-300 [MeSH Supplementary Concept]
- NK13650A [MeSH Supplementary Concept]
- NK13650B [MeSH Supplementary Concept]
- NPI 2358 [MeSH Supplementary Concept]
- PJ 147 [MeSH Supplementary Concept]
- PJ 157 [MeSH Supplementary Concept]
- SCH 64874 [MeSH Supplementary Concept]
- TW-01 compound [MeSH Supplementary Concept]
- acetylapoaranotin [MeSH Supplementary Concept]
- adametizine A [MeSH Supplementary Concept]
- adametizine B [MeSH Supplementary Concept]
- aplaviroc [MeSH Supplementary Concept]
- asperazine A [MeSH Supplementary Concept]
- asterripeptide B [MeSH Supplementary Concept]
- asterripeptide C [MeSH Supplementary Concept]
- bacillusamide A [MeSH Supplementary Concept]
- bacillusamide B [MeSH Supplementary Concept]
- bis-N-norgliovictin [MeSH Supplementary Concept]
- brevianamide S [MeSH Supplementary Concept]
- cabotegravir [MeSH Supplementary Concept]
- callysponine A [MeSH Supplementary Concept]
- chetracin B [MeSH Supplementary Concept]
- chetracin C [MeSH Supplementary Concept]
- cyclo(D-trans-Hyp-L-Leu) [MeSH Supplementary Concept]
- cyclo-(4-S-hydroxy-R-proline-R-isoleucine) [MeSH Supplementary Concept]
- cyclo-(L-Pro-L-Phe) [MeSH Supplementary Concept]
- cyclo-(glycyl-L-tyrosyl)-4,4-dimethylallyl ether [MeSH Supplementary Concept]
- cyclo-L-glycyl-L-2-allylproline [MeSH Supplementary Concept]
- deferricoprogen [MeSH Supplementary Concept]
- deoxyapoaranotin [MeSH Supplementary Concept]
- deoxymicelianamide [MeSH Supplementary Concept]
- desferricoprogen [MeSH Supplementary Concept]
- dihydrocryptoechinuline D [MeSH Supplementary Concept]
- dimerumic acid [MeSH Supplementary Concept]
- effusin A [MeSH Supplementary Concept]
- eleutherazine A [MeSH Supplementary Concept]
- eleutherazine B [MeSH Supplementary Concept]
- ent-cycloechinulin [MeSH Supplementary Concept]
- epelsiban [MeSH Supplementary Concept]
- epidiselenodiketopiperazine [MeSH Supplementary Concept]
- erythrochelin [MeSH Supplementary Concept]
- glionitrin A [MeSH Supplementary Concept]
- glionitrin B [MeSH Supplementary Concept]
- haenamindole [MeSH Supplementary Concept]
- iso-pestalazine A [MeSH Supplementary Concept]
- leporizine A [MeSH Supplementary Concept]
- leporizine B [MeSH Supplementary Concept]
- leporizine C [MeSH Supplementary Concept]
- luteoalbusin A [MeSH Supplementary Concept]
- luteoalbusin B [MeSH Supplementary Concept]
- mycocyclosin [MeSH Supplementary Concept]
- naseseazine A [MeSH Supplementary Concept]
- naseseazine B [MeSH Supplementary Concept]
- nocardioazine A [MeSH Supplementary Concept]
- nocardioazine B [MeSH Supplementary Concept]
- novoamauromine [MeSH Supplementary Concept]
- peniciadametizine A [MeSH Supplementary Concept]
- peniciadametizine B [MeSH Supplementary Concept]
- pestalazine A [MeSH Supplementary Concept]
- pestalazine B [MeSH Supplementary Concept]
- phenylahistin [MeSH Supplementary Concept]
- protubonine A [MeSH Supplementary Concept]
- protubonine B [MeSH Supplementary Concept]
- saroclazine A [MeSH Supplementary Concept]
- saroclazine B [MeSH Supplementary Concept]
- saroclazine C [MeSH Supplementary Concept]
- terramide A [MeSH Supplementary Concept]
- tetroazolemycin A [MeSH Supplementary Concept]
- tetroazolemycin B [MeSH Supplementary Concept]
- versicamide H [MeSH Supplementary Concept]
- waspergillamide A [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
Validated automatic mappings to BTNT
- Piperazinedione [NCIt concept]

Keyword's position in hierarchy(ies) :

You can consult :

recommendations
documents concerning education
documents for patients